Dated: June 20, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: BGI-126CPCN (PATENT)

In re Patent Application of: Markus Pompejus *et al*.

Application No.: 10/781014

Confirmation No.: 2283

Filed: February 17, 2004

Art Unit: 1652

For:

CORYNEBACTERIUM GLUTAMICUM

GENES ENCODING PROTEINS INVOLVED IN CARBON METABOLISM AND ENERGY

PRODUCTION

Examiner: C. L. Fronda

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO Form SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

For the Examiner's convenience in reviewing this continuation application, Applicants submit a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. Specifically, references A1, B1-B3 and C3-C20 were previously cited and submitted to the Office in U.S. Application Serial No. 09/602,740, filed June 23, 2000 (Atty. Docket No. BGI-126CP), of which this application is a continuation and to which this

06/23/2006 MAHMED1 00000095 120080 10781014

02 FC:1806

180.00 DA

Docket No.: BGI-126CPCN Application No.: 10/781014

application claims priority. In accordance with 37 CFR §1.98(d), these references are not enclosed herewith, but will be provided upon request. In addition, this Information Disclosure Statement presents references C1-C2, not previously submitted to the Office, which are enclosed herewith in accordance with 37 CFR §1.97.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. BGI-126CPCN.

Dated: June 20, 2006

MLZ/MXG/mch

Respectfully submitted

ourohy Maria Laccotripe Zacharakis

Registration No.: 56,266

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/781014-Conf. #2283	
IN.	NFORMATION	N DI	SCLOSURE	Filing Date	February 17, 2004	
S	TATEMENT	BY /	APPLICANT	First Named Inventor	Markus POMPEJUS	
				Art Unit	1652	
	(Use as many sh	ieets as	; necessary)	Examiner Name	C. L. Fronda	
Sheet	1	of	2	Attorney Docket Number	BGI-126CPCN	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1*	2002/0197605	12-26-2002	Nakagawa, Satoshi et al.			

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Examiner Cite Initials* No.	Cite No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
	B1	WO01/04322-A1	01-18-2001	Degussa-Hüls Aktiengesellschaft			
	B2	WO01/04325-A1	01-18-2001	Degussa-Hüls Aktiengesellschaft			
	B3	EP1108790-A2	06-20-2001	Kyowa Hakko Kogyo Co., Ltd.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	GenBank Accession No. CAB09261, DevB [Mycobacterium tuberculosis], Cole , S.T. et al., May 28, 1997	
	C2	Peters-Wendisch, Petra G. et al, "Pyruvate carboxylase from Corynebacterium glutamicum: characterization, expression and inactivation of the pyc gene," Microbiology, Vol. 144:915-927 (1998	
	C3*	Abrams et al. Alignment to US-08-411-795B-398/C. February 1997	
	C4*	Bathe, B. et al, "A physical and genetic map of the Corynebacterium glutamicum ATCC 13032 chromosome," Mol. Gen. Genet., Vol. 252(3):255-265 (1996)	
	C5*	Cole, S.T. et al, "Deciphering the biology of <i>Mycobacterium tuberculosis</i> from the complete genome sequence," <i>Nature</i> , Vol. 393(6685):537-544 (1998)	
	C6*	Collard, F. et al, "Identification of the cDNA encoding human 6-phosphogluconolactonase, the enzyme catalyzing the second step of the pentose phosphate pathway(1)," FEBS Lett., Vol. 459(2):223-226 (1999)	
	C7*	Eikmanns, B.J. et al, "The phosphoenolpyruvate carboxylase gene of <i>Corynebacterium glutamicum</i> : Molecular cloning, nucleotide sequence, and expression," <i>Mol. Gen. Genet.</i> , Vol. 218(2):330-339 (1989)	
	C8*	EMBL Accession No O06814 for "6-phosphogluconolactonase (EC 3.1.1.31) (6PGL)."	
	C9*	Fleischman et al, Alignment to US-09-103-840A-2. September 2001	
	C10*	GenBank Accession No. CAB66415, "6-phosphogluconolactonase-like protein (Arabidopsis thaliana)," January 19, 2000	
	C11*	GenBank Accession No. AL132956, "Arabidopsis thaliana DNA chromosome 3, BAC clone F2K15," January 19, 2000	
	C12*	GenBank Accession No. CAB57866, "6 phosphogluconolactonase (Homo sapiens)," October 8, 1999	

Examiner	Date	
Signature	Cons	sidered

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
5555				Application Number	10/781014-Conf. #2283	
INF	ORMATION	DI	SCLOSURE	Filing Date	February 17, 2004	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Markus POMPEJUS	
				Art Unit	1652	
(Use as many sheets as necessary)			necessary)	Examiner Name	C. L. Fronda	
Sheet	2	of	2	Attorney Docket Number	BGI-126CPCN	

C13*	GenBank Accession No. HSA243972, "Homo sapiens mRNA for 6-phosphogluconolactonase	
	(gPGL gene)," October 8, 1999	
C14*	GenBank Accession No. AF029673, "Pseudomonas aeruginosa HexR (hexR), glucose-g-phosphate1-dehydrogenase (zwf), 6-phosphogluconolactonase (pgl), and 2-keto-3deoxy-6-phosphogluconolactonase (eda) genes, complete cds," April 2, 1999	
C15*	GenBank Accession No. AAD22666, "6-phosphogluconolactonase (Pseudomonas	
	aeruginosa)," April 2, 1999	
C16*	Krubasik et al., GenBank Accession No. NP 600792 (March, 2001) 6-	
	phosphogluconolactonase/Glucosamine-6-phosphate isomerase/deaminase. A 235 amino	
	acid protein from C. glutamicum	
C17*	Ma, JF et al, "Cloning and characterization of the Pseudomonas aeruginosa zwf gene	
	encoding glucose-6-phosphate dehydrogenase, an enzyme important in resistance to methyl	ļ
	viologen (paraquat)," J. Bacteriol., Vol. 180(7):1741-1749 (1998)	
C18*	Marra et al, GenBank Accession Number AA915356 (April, 1998) vz29z08.r1	Į.
	Soares_thymus_2NbMT Mus musculus cDNA clone	
C19*	Peters-Wendisch, P.G. et al, "Pyruvate carboxylase as an anaplerotic enzyme in	
	Corynebacterium glutamicum," Microbiology, Vol. 143:1095-1103 (1997)	
C20*	Rieger et al, Glossary of Genetics (1991), p. 16	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		_
Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.